Acta Radiol

1. YANG YY, Liu ZM, Peng RC
   Diagnostic performance of 18F-labeled PSMA PET/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
   Acta Radiol. 2023;64:2791-2801.
   

   >> Share

   
   
2. ONAY A, Bakir B, Colak E, Turkbey B, et al
   Pathology outcomes of PI-RADS category 4 lesions in the peripheral zone: impact of MRI signal features and lesion size.
   Acta Radiol. 2026;67:280-289.
   

   >> Share

   
   

   
   AJR Am J Roentgenol

3. NEDELCU A, Oerther B, Benkendorff A, Dieckbreder S, et al
   PI-RADS Version 2.1 for Prostate MRI Interpretation: Associations of Study Quality and Cancer Detection Metrics-A Systematic Review and Meta-Analysis.
   AJR Am J Roentgenol. 2025 Oct 15. doi: 10.2214/AJR.25.33583.
   

   >> Share

   
   
4. SANMUGALINGAM N, Sushentsev N, Lee KL, Caglic I, et al
   The PRECISE Recommendations for Prostate MRI in Patients on Active Surveillance for Prostate Cancer: A Critical Review.
   AJR Am J Roentgenol. 2023;221:649-660.
   

   >> Share

   
   

   
   Am J Clin Pathol

5. WOBKER SE, Williamson SR, Kenigsberg A, Muthusamy S, et al
   Intraductal histiocytes as a simulant of intraductal carcinoma of the prostate.
   Am J Clin Pathol. 2026;165:aqag004.
   

   >> Share

   
   

   
   BJU Int

6. ALHUSSEINAWI H, Sander L, Rosenvinge PM, Jensen SL, et al
   Low- versus standard- pneumoperitoneum in patients undergoing robot-assisted radical prostatectomy: a randomised, triple-blinded study.
   BJU Int. 2023;132:560-567.
   

   >> Share

   
   
7. CUSSENOT O, Cancel-Tassin G, Rao SR, Woodcock DJ, et al
   Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
   BJU Int. 2023;132:472-484.
   

   >> Share

   
   
8. HAAPIAINEN H, Murtola TJ, Koskimaki J, Riikonen J, et al
   Robot-assisted versus three-dimensional laparoscopic radical prostatectomy: 12-month outcomes of a randomised controlled trial.
   BJU Int. 2023;132:505-511.
   

   >> Share

   
   
9. KHANNA Y, Chinni V, Gnanasambantham K, Paul E, et al
   Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?
   BJU Int. 2026;137:619-628.
   

   >> Share

   
   
10. MA L, Lu R, Dong Z
    Comment on 'Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights'.
    BJU Int. 2026 Mar 6. doi: 10.1111/bju.70197.
    

    >> Share

    
    
11. MARQUIS A, Rastinehad AR
    Reply to 'Comment on novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer'.
    BJU Int. 2026 Mar 6. doi: 10.1111/bju.70198.
    

    >> Share

    
    
12. DELONGCHAMPS NB, Peltier A, Potiron E, Bladou F, et al
    Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study.
    BJU Int. 2026 Mar 11. doi: 10.1111/bju.70220.
    

    >> Share

    
    
13. JACKSON SR, Yu P, Sowter S, Occhipinti S, et al
    The prostate cancer electronic health (eHealth) literacy instrument: a tool for eHealth design and patient communication.
    BJU Int. 2026 Mar 12. doi: 10.1111/bju.70225.
    

    >> Share

    
    

    
    BMC Cancer

14. WENZEL M, Filzmayer M, Siech C, Le QC, et al
    Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and >/= 10 bone metastases receiving apalutamide: a real-world cohort.
    BMC Cancer. 2026 Mar 2. doi: 10.1186/s12885-026-15803.
    

    >> Share

    
    

    
    Br J Cancer

15. TURNHAM DJ, French R, Frame FM, Meniel VS, et al
    Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity.
    Br J Cancer. 2026 Mar 3. doi: 10.1038/s41416-026-03359.
    

    >> Share

    
    
16. DIXON KM, Lui GYL, Kovacevic Z, Zhang D, et al
    Correction to: Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
    Br J Cancer. 2026 Mar 2. doi: 10.1038/s41416-026-03353.
    

    >> Share

    
    
17. YANG J, Ryniawec JM, de Oliveira Pessoa D, Coope MR, et al
    Transient centrosome loss in cultured prostate epithelial cells induces chromosomal instability to produce an oncogenic genotype that correlates with poor clinical outcomes.
    Br J Cancer. 2026;134:924-938.
    

    >> Share

    
    

    
    Br J Radiol

18. MONIKA H, Komalpreet K, Watts A, Harmandeep S, et al
    99mTc-HYNIC-PSMA-11 Whole-Body SPECT/CT: A Clinically Viable Alternative to 68Ga-PSMA PET/CT in patients with Prostate Cancer.
    Br J Radiol. 2026 Mar 12:tqag052. doi: 10.1093.
    

    >> Share

    
    
19. ELSAKA R, Hegazy H, Eldrieny A, Kotb M, et al
    Impact of PSMA PET/CT on Initial Staging and Planning of Definitive Radiation Therapy in Prostate Cancer.
    Br J Radiol. 2026 Mar 10:tqag057. doi: 10.1093.
    

    >> Share

    
    
20. VURAL M, Atasoy D, Durmaz S, Ozbozduman K, et al
    MRI Pathway for Small Volume Prostate Gland Index Lesions; A Single Center Retrospective Analysis.
    Br J Radiol. 2025 Nov 10:tqaf269. doi: 10.1093.
    

    >> Share

    
    

    
    Cancer

21. WANG TF, Clarke A, Rath M, Yoo S, et al
    Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents.
    Cancer. 2026;132:e70266.
    

    >> Share

    
    
22. BORGERT B, Kay H, Basak RS, Usinger D, et al
    Impact of smoking on health-related quality-of-life outcomes in prostate cancer survivors.
    Cancer. 2026;132:e70336.
    

    >> Share

    
    
23. GANN PH, Stackhouse N, Gastala N, Ma W, et al
    A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population.
    Cancer. 2026;132:e70340.
    

    >> Share

    
    

    
    Cancer Res

24. GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
    Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
    Cancer Res. 2023;83:3340-3353.
    

    >> Share

    
    
25. ALIZADEH-GHODSI M, Goldstein AS
    Polyamine Metabolism as a Metabolic Vulnerability in Prostate Cancer Treated with Supraphysiological Androgens.
    Cancer Res. 2026;86:1095-1097.
    

    >> Share

    
    
26. BREVI A, Lorenzoni M, Caputo S, Yamada Y, et al
    Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression.
    Cancer Res. 2026 Mar 5. doi: 10.1158/0008-5472.CAN-25-2704.
    

    >> Share

    
    

    
    Clin Cancer Res

27. MCKAY RR, Nazari SS, Elliott A, Smith N, et al
    Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.
    Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-4293.
    

    >> Share

    
    

    
    Curr Treat Options Oncol

28. DAVOUDI F, Moradi A, Becker TM, Lock JG, et al
    Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.
    Curr Treat Options Oncol. 2023;24:1451-1471.
    

    >> Share

    
    

    
    Hum Pathol

29. COLLINS K, Gupta S, Cheng L
    Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance.
    Hum Pathol. 2026;169:106018.
    

    >> Share

    
    

    
    Int J Cancer

30. BERZOTI-COELHO MG, de Mello FN, Tahira AC, Fortes GN, et al
    PVT1 lincRNA signals an androgen-dependent transcriptional activation program of oncogenes in prostate cancer cells.
    Int J Cancer. 2026 Mar 6. doi: 10.1002/ijc.70417.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

31. ZILLI T, Jorcano S, Bral S, Symon Z, et al
    Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2023;117:791-798.
    

    >> Share

    
    

    
    Int J Urol

32. HIBINO T, Kato M, Tsuzuki T, Nishikimi T, et al
    Total Positive Margin Length as a Novel Prognostic Indicator After Radical Prostatectomy.
    Int J Urol. 2026;33:e70395.
    

    >> Share

    
    
33. UCHIDA K, Watanabe H, Matsushita Y, Tamura K, et al
    Robot-Assisted Radical Cystectomy Using the Hinotori Surgical System in Patients With Previous Prostate Cancer Treatment: A Single-Institution Case Series.
    Int J Urol. 2026;33:e70383.
    

    >> Share

    
    

    
    J Natl Cancer Inst

34. LU-YAO G, Nikita N, Keith SW, Gandhi K, et al
    Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer.
    J Natl Cancer Inst. 2026 Mar 7:djag061. doi: 10.1093.
    

    >> Share

    
    
35. BOSLAND MC
    RE: Prostate cancer clinicopathological presentation in South-East Africa during the 2010 decade.
    J Natl Cancer Inst. 2026 Mar 7:djag059. doi: 10.1093.
    

    >> Share

    
    
36. PALLER CJ, Wei S, Schumacher M, Rabizadeh D, et al
    Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in european American and african American men.
    J Natl Cancer Inst. 2026 Mar 10:djag036. doi: 10.1093.
    

    >> Share

    
    

    
    J Nucl Med

37. MERCOLLI L, Mingels C, Manzini G, Cumming P, et al
    [(177)Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.
    J Nucl Med. 2023;64:1570-1573.
    

    >> Share

    
    
38. MOAR EF, Keilholz M, Sheikh GT, Werner RA, et al
    PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOG.
    J Nucl Med. 2025 Dec 30:jnumed.125.271324. doi: 10.2967/jnumed.125.271324.
    

    >> Share

    
    
39. MORADPOUR M, Moradi Tuchayi A, Yadav S, Jiang F, et al
    Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.
    J Nucl Med. 2026 Mar 5:jnumed.125.271296. doi: 10.2967/jnumed.125.271296.
    

    >> Share

    
    
40. GHODSI A, Demirci RA, Gulati R, Nelson PS, et al
    Prognostic Value of Cycle 1 SPECT SUV(mean) in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA-617.
    J Nucl Med. 2026 Mar 12:jnumed.125.271593. doi: 10.2967/jnumed.125.271593.
    

    >> Share

    
    

    
    J Urol

41. DENG R, Li D, Wu J, Tian S, et al
    Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naive Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.
    J Urol. 2026;215:408-420.
    

    >> Share

    
    
42. COOPERBERG MR
    Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026): Sound Science, Soft Power.
    J Urol. 2026 Mar 6:101097JU0000000000004999. doi: 10.1097/JU.0000000000004999.
    

    >> Share

    
    

    
    Lancet Oncol

43. KARPINSKI MJ, Civan C, Rauscher I, Guven O, et al
    New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.
    Lancet Oncol. 2026 Mar 9:S1470-2045(26)00016.
    

    >> Share

    
    

    
    N Engl J Med

44. 
    European Study of Prostate Cancer Screening - 23-Year Follow-up.
    N Engl J Med. 2026;394:1144.
    

    >> Share

    
    

    
    Nat Rev Urol

45. MAYOR N, Ahmed HU
    Prostate cancer screening: weighing the benefits and harms.
    Nat Rev Urol. 2026 Mar 6. doi: 10.1038/s41585-026-01133.
    

    >> Share

    
    

    
    Oncogene

46. GUCHHAIT K, Yoon HS, An HS, Shin S, et al
    Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD).
    Oncogene. 2026 Mar 9. doi: 10.1038/s41388-026-03717.
    

    >> Share

    
    

    
    Oncol Rep

47. BOKOBZA SM, Ye L, Kynaston HG, Jiang WG, et al
    [Retracted] Growth and differentiation factor?9 promotes adhesive and motile capacity of prostate cancer cells by up?regulating FAK and Paxillin via Smad dependent pathway.
    Oncol Rep. 2026;55:84.
    

    >> Share

    
    

    
    PLoS One

48. 
    Retraction: Upregulation of SATB1 Is Associated with Prostate Cancer Aggressiveness and Disease Progression.
    PLoS One. 2026;21:e0344761.
    

    >> Share

    
    
49. ZHU Z, Zhu Y, Wu H, Zhou P, et al
    Application and efficacy of the pubovesical complex-preserving technique in intrafascial laparoscopic radical prostatectomy: A propensity score-matched analysis.
    PLoS One. 2026;21:e0342248.
    

    >> Share

    
    

    
    Prostate

50. KOGUCHI D, Tsumura H, Tabata KI, Satoh T, et al
    Defining Favorable Prognosis in Bone Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.
    Prostate. 2026 Mar 3. doi: 10.1002/pros.70152.
    

    >> Share

    
    
51. TARRAGA-HONRUBIA MA, Salinas-Sanchez AS, Navarro-Jimenez S, Lorenzo-Sanchez MV, et al
    [(18)F] PSMA PET-CT and [(18)F] Choline PET-CT in the Diagnosis of High-Risk Localized Prostate Cancer: Comparation of Both Tests.
    Prostate. 2026 Mar 3. doi: 10.1002/pros.70150.
    

    >> Share

    
    
52. YANG T, Wang X, Deng Y, Liu H, et al
    Tumor Prostate-Specific Antigen Density Can Predict Tumor Aggressiveness and Heterogeneity in Prostate Cancer.
    Prostate. 2026 Mar 6. doi: 10.1002/pros.70153.
    

    >> Share

    
    
53. SAYAN M, Tuac Y, Qian Z, Dall CP, et al
    Surveillance Versus Treatment for Favorable Intermediate-Risk Prostate Cancer and Mortality-Risk.
    Prostate. 2026 Mar 9. doi: 10.1002/pros.70156.
    

    >> Share

    
    
54. ZHENG R, Daniels JP, Mirocha JM, Hernandez-Tirado A, et al
    Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
    Prostate. 2026 Mar 12. doi: 10.1002/pros.70154.
    

    >> Share

    
    

    
    Radiology

55. GIGANTI F, Allen C, Dickinson L, Punwani S, et al
    MRI for Active Surveillance in Prostate Cancer: How I Do It.
    Radiology. 2026;318:e242164.
    

    >> Share

    
    

    
    Urology

56. COSKUN B, Ocakoglu G, Yetemen M, Kaygisiz O, et al
    Can ChatGPT, an Artificial Intelligence Language Model, Provide Accurate and High-quality Patient Information on Prostate Cancer?
    Urology. 2023;180:35-58.
    

    >> Share

    
    
57. BRAUN AE 3RD, Washington SL, Cowan JE, Hampson LA, et al
    Impact of Stress Urinary Incontinence After Radical Prostatectomy on Time to Intervention, Quality of Life and Work Status.
    Urology. 2023;180:242-248.
    

    >> Share

    
    
58. SOPUTRO NA, Ferguson EL, Ramos-Carpinteyro R, Sauer Calvo R, et al
    Low Risk of Postoperative Hernia Following Single-port Robot-assisted Radical Prostatectomy: A Report From the Single-port Advanced Research Consortium (SPARC).
    Urology. 2023;180:151-159.
    

    >> Share

    
    
59. SOPUTRO NA, Ferguson EL, Ramos-Carpinteyro R, Chavali JS, et al
    The Transition Toward Opioid-sparing Outpatient Radical Prostatectomy: A Single Institution Experience With Three Contemporary Robotic Approaches.
    Urology. 2023;180:140-150.
    

    >> Share

    
    
60. BHANJI Y, Mamawala M, de la Calle CM, Landis P, et al
    Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) Magnetic Resonance Imaging Scoring to Predict Clinical Outcomes in Active Surveillance for Grade Group 1 Prostate Cancer.
    Urology. 2023;180:194-199.
    

    >> Share

    
    
61. DAVIS KM, Luta G, Hoffman RM, Lobo T, et al
    Patient-reported psychological and prostate cancer-specific functional outcomes among men with low-risk prostate cancer two years after diagnosis: The PREPARE prospective cohort study.
    Urology. 2026 Mar 10:S0090-4295(26)00154-8. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share